VULM 993

Drug Profile

VULM 993

Latest Information Update: 14 Apr 2010

Price : $50

At a glance

  • Originator VULM
  • Developer Zentiva
  • Class
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 15 Sep 2003 Slovakofarma has merged with Leciva to form Zentiva
  • 31 Dec 2001 This agent is still in active development
  • 04 May 1999 Preclinical development for Hypertension in Slovakia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top